Payment overview · 2025
General Payments
$7,151.72
148 reported records · 32 companies
Healthcare provider profile · identity verified
Devin Michael Bourgeois, MD
Allopathic & Osteopathic Physicians|Internal Medicine · THIBODAUX, LA · NPI 1669913943
Verified facts
What the public records show
CMS Open Payments records show Devin Michael Bourgeois, MD received $7,151.72 in general payments during 2025 across 148 reported records.
Lilly USA, LLC accounted for 57.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Nexletol, Ozempic, Qulipta, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy, Veozah, Vraylar, Wegovy, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 461 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 461 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 386 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 703 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 734 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $4,136.65 | 57.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $406.57 | 5.7% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $255.23 | 3.6% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $243.84 | 3.4% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $231.04 | 3.2% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $192.00 | 2.7% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $173.30 | 2.4% | 13 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$172.44 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $137.61 | 1.9% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $118.92 | 1.7% | 6 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $105.30 | 1.5% | 5 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $101.21 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $85.61 | 1.2% | 5 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $73.92 | 1.0% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $72.99 | 1.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.90 | 1.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.26 | 0.9% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $62.63 | 0.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.35 | 0.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $55.71 | 0.8% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $53.85 | 0.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.46 | 0.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $39.76 | 0.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.51 | 0.5% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $32.18 | 0.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.32 | 0.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.85 | 0.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.13 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.02 | 0.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.24 | 0.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.96 | 0.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.96 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $3,750.00 | 3 |
| Food and Beverage | $3,005.83 | 142 |
| Travel and Lodging | $331.35 | 1 |
| Education | $64.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $1,237.19 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $259.47 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $234.53 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $211.13 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $205.81 | 10 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $172.44 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $170.57 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $143.35 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $135.38 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $123.53 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.54 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $118.92 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $115.62 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $105.30 | 5 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $101.21 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $85.61 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $84.71 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $84.71 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $73.92 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $72.99 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $70.90 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $68.26 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $62.63 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.35 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $55.71 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.30 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $53.85 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.90 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.42 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.42 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.42 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.46 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.92 | 2 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $32.18 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 734 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 374 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 286 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 461 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 131 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 386 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 703 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 269 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 98 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
131 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
119 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
374 | 48 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
461 | 78 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
87 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 24 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
153 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
461 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
386 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
105 | 21 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
269 | 30 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
95 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
703 | 127 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
98 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
269 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
734 | 87 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
286 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1410 | 235 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1321 | 279 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1074 | 221 |
| Gabapentin | Gabapentin | 1046 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 995 | 221 |
| Metformin Hcl | Metformin Hcl | 869 | 194 |
| Trazodone Hcl | Trazodone Hcl | 842 | 137 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 832 | 190 |
| Metoprolol Succinate | Metoprolol Succinate | 816 | 155 |
| Eliquis | Apixaban | 734 | 87 |
| Ozempic | Semaglutide | 703 | 127 |
| Escitalopram Oxalate | Escitalopram Oxalate | 659 | 101 |
| Memantine Hcl | Memantine Hcl | 644 | 97 |
| Losartan Potassium | Losartan Potassium | 620 | 137 |
| Potassium Chloride | Potassium Chloride | 609 | 105 |
| Furosemide | Furosemide | 595 | 126 |
| Alprazolam | Alprazolam | 591 | 108 |
| Sertraline Hcl | Sertraline Hcl | 587 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 581 | 117 |
| Quetiapine Fumarate | Quetiapine Fumarate | 575 | 82 |
| Lisinopril | Lisinopril | 571 | 124 |
| Carvedilol | Carvedilol | 535 | 129 |
| Mirtazapine | Mirtazapine | 523 | 98 |
| Omeprazole | Omeprazole | 518 | 119 |
| Duloxetine Hcl | Duloxetine Hcl | 478 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 475 | 89 |
| Jardiance | Empagliflozin | 461 | 78 |
| Ezetimibe | Ezetimibe | 449 | 118 |
| Nifedipine Er | Nifedipine | 421 | 96 |
| Donepezil Hcl | Donepezil Hcl | 410 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 402 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 388 | 105 |
| Mounjaro | Tirzepatide | 386 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 381 | 75 |
| Pregabalin | Pregabalin | 377 | 85 |
| Farxiga | Dapagliflozin Propanediol | 374 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 370 | 128 |
| Famotidine | Famotidine | 364 | 83 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 329 | 72 |
| Allopurinol | Allopurinol | 313 | 72 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 311 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 299 | 91 |
| Clonazepam | Clonazepam | 299 | 47 |
| Spironolactone | Spironolactone | 299 | 53 |
| Bupropion Xl | Bupropion Hcl | 296 | 57 |
| Tramadol Hcl | Tramadol Hcl | 295 | 87 |
| Fluoxetine Hcl | Fluoxetine Hcl | 289 | 52 |
| Gemtesa | Vibegron | 286 | 31 |
| Meloxicam | Meloxicam | 283 | 64 |
| Januvia | Sitagliptin Phosphate | 280 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 278 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 275 | 66 |
| Celecoxib | Celecoxib | 269 | 46 |
| Rexulti | Brexpiprazole | 269 | 30 |
| Metformin Hcl Er | Metformin Hcl | 265 | 56 |
| Levetiracetam | Levetiracetam | 261 | 37 |
| Prednisone | Prednisone | 239 | 120 |
| Torsemide | Torsemide | 235 | 41 |
| Baclofen | Baclofen | 229 | 41 |
| Montelukast Sodium | Montelukast Sodium | 229 | 51 |
| Doxazosin Mesylate | Doxazosin Mesylate | 227 | 52 |
| Buspirone Hcl | Buspirone Hcl | 219 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 216 | 41 |
| Lorazepam | Lorazepam | 191 | 39 |
| Bumetanide | Bumetanide | 190 | 50 |
| Ropinirole Hcl | Ropinirole Hcl | 183 | 33 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 177 | 23 |
| Glipizide Er | Glipizide | 175 | 39 |
| Valsartan | Valsartan | 175 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 172 | 28 |
| Aripiprazole | Aripiprazole | 170 | 28 |
| Chlorthalidone | Chlorthalidone | 158 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 157 | 38 |
| Alendronate Sodium | Alendronate Sodium | 153 | 38 |
| Novolog Flexpen | Insulin Aspart | 153 | 34 |
| Xarelto | Rivaroxaban | 153 | 20 |
| Finasteride | Finasteride | 149 | 33 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 149 | 29 |
| Divalproex Sodium | Divalproex Sodium | 142 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 138 | 58 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 33 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 136 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 135 | 25 |
| Linzess | Linaclotide | 131 | 32 |
| Diazepam | Diazepam | 130 | 35 |
| Megestrol Acetate | Megestrol Acetate | 128 | 31 |
| Colestipol Hcl | Colestipol Hcl | 127 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 126 | 23 |
| Simvastatin | Simvastatin | 125 | 32 |
| Temazepam | Temazepam | 122 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 121 | 47 |
| Azithromycin | Azithromycin | 120 | 94 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 38 |
| Myrbetriq | Mirabegron | 119 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 116 | 17 |
| Ondansetron Odt | Ondansetron | 116 | 51 |
| Oxybutynin Chloride | Oxybutynin Chloride | 116 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 115 | 68 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 110 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 110 | 22 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 107 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 106 | 24 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 106 | 20 |
| Trulicity | Dulaglutide | 105 | 21 |
| Methocarbamol | Methocarbamol | 104 | 33 |
| Olanzapine | Olanzapine | 102 | 20 |
| Sucralfate | Sucralfate | 102 | 24 |
| Fluconazole | Fluconazole | 100 | 63 |
| Naproxen | Naproxen | 100 | 40 |
| Humalog Kwikpen U-100 | Insulin Lispro | 98 | 20 |
| Rybelsus | Semaglutide | 98 | 19 |
| Midodrine Hcl | Midodrine Hcl | 97 | 20 |
| Latanoprost | Latanoprost | 96 | 21 |
| Entresto | Sacubitril/Valsartan | 95 | 13 |
| Topiramate | Topiramate | 95 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 24 |
| Risperidone | Risperidone | 93 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 92 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 29 |
| Atenolol | Atenolol | 88 | 21 |
| Estradiol | Estradiol | 87 | 23 |
| Galantamine Er | Galantamine Hbr | 87 | 16 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 87 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 16 |
| Clonidine Hcl | Clonidine Hcl | 85 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 85 | 15 |
| Glipizide | Glipizide | 85 | 27 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 83 | 26 |
| Glimepiride | Glimepiride | 83 | 22 |
| Telmisartan | Telmisartan | 81 | 30 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 77 | 30 |
| Benazepril Hcl | Benazepril Hcl | 76 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 76 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 75 | 25 |
| Oxcarbazepine | Oxcarbazepine | 73 | suppressed |
| Cilostazol | Cilostazol | 72 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 71 | 14 |
| Lactulose | Lactulose | 71 | 23 |
| Levofloxacin | Levofloxacin | 69 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 26 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 66 | 25 |
| Lovastatin | Lovastatin | 64 | 17 |
| Meclizine Hcl | Meclizine Hcl | 63 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 60 | 14 |
| Repatha Sureclick | Evolocumab | 60 | 17 |
| Mupirocin | Mupirocin | 58 | 34 |
| Ranolazine Er | Ranolazine | 58 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 11 |
| Valacyclovir | Valacyclovir Hcl | 54 | 19 |
| Vascepa | Icosapent Ethyl | 54 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 53 | 17 |
| Vraylar | Cariprazine Hcl | 53 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 52 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Azelastine Hcl | Azelastine Hcl | 51 | 15 |
| Fenofibrate | Fenofibrate | 51 | 11 |
| Propranolol Hcl | Propranolol Hcl | 51 | 14 |
| Hydrocortisone | Hydrocortisone | 49 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 40 |
| Ramipril | Ramipril | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 28 |
| Ketoconazole | Ketoconazole | 45 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 14 |
| Colchicine | Colchicine | 43 | 13 |
| Lacosamide | Lacosamide | 43 | suppressed |
| Brilinta | Ticagrelor | 42 | suppressed |
| Nystatin | Nystatin | 42 | 31 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | suppressed |
| Xifaxan | Rifaximin | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 37 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 40 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 40 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 40 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 39 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 29 |
| Propranolol Hcl Er | Propranolol Hcl | 39 | suppressed |
| Anastrozole | Anastrozole | 38 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 38 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 37 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 36 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 35 | 25 |
| Metolazone | Metolazone | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | 19 |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 32 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 32 | 12 |
| Lidocaine Hcl | Lidocaine Hcl | 32 | 21 |
| Cephalexin | Cephalexin | 31 | 24 |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Entacapone | Entacapone | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 21 |
| Kerendia | Finerenone | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 21 |
| Digoxin | Digoxin | 27 | suppressed |
| Invokana | Canagliflozin | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Trimethoprim | Trimethoprim | 27 | suppressed |
| Wegovy | Semaglutide | 27 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 12 |
| Roflumilast | Roflumilast | 25 | suppressed |
| Timolol Maleate | Timolol Maleate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 22 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Nexletol | Bempedoic Acid | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Minoxidil | Minoxidil | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Entecavir | Entecavir | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 14 | suppressed |
| Veozah | Fezolinetant | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | 12 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Linezolid | Linezolid | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Nystop | Nystatin | 11 | 11 |
| Qulipta | Atogepant | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tyrvaya | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,151.72 · 148 records | Lilly USA, LLC | ABRYSVO, AREXVY, Auvelity, Azstarys, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, GEMTESA, JARDIANCE, JATENZO, Kerendia, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROTEGE RX, QULIPTA, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, SPRAVATO, Saxenda, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, YUPELRI, ZAVZPRET, ZEPBOUND | 33 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error